Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegloticase - Horizon Therapeutics

Drug Profile

Pegloticase - Horizon Therapeutics

Alternative Names: KRYSTEXXA; Methoxypolyethylene glycol uricase; PEG urate oxidase; PEG-uricase; PEGylated uricase; Polyethylene glycol-uricase; Puricase; Urate-oxidase-PEG

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Duke University; Mountain View Pharmaceuticals
  • Developer Horizon Pharma Rheumatology; Savient Pharmaceuticals
  • Class Antigouts; Oxidoreductases; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Urate oxidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gout
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Gout

Most Recent Events

  • 10 Nov 2023 Updated efficacy data from the phase IV MIRROR RCT trial in Gout presented at ACR Convergence 2023 (ACR-2023)
  • 31 May 2023 Updated efficacy data from the phase IV MIRROR RCT trial in Gout released by Horizon Therapeutics
  • 14 Nov 2022 Efficacy data from the phase IV MIRROR OL trial in Gout presented at the American College of Rheumatology Convergence 2022 (ACR-2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top